Athenecia Faggins of Minaris Advanced Therapies discusses raw material qualification, supplier management, testing, and risk control for advanced therapy manufacturing.
|Articles|November 1, 2019
Evonetix Relocates to New Facility in Cambridge, UK
Author(s)BioPharm International Editors
The new facility is 15,000 ft2, which includes 8000 ft2 of lab space and 7000 ft2 of office space.
Advertisement
Evonetix, a synthetic biology company previously located in Chesterford Research Park, United Kingdom, announced it relocated to a new facility in Coldham’s Business Park, Cambridge, UK on Oct. 30, 2019.
The new facility is 15,000 ft2, which includes 8000 ft2 of lab space and 7000 ft2 of office space, the company said in a press release. The company currently houses 40 employees and will look to recruit further staff to join its teams of physicists, electronics and software engineers, chemists, biologists, and molecular biologists at its new location.
“Synthetic biology has the potential to solve some of the world’s most intractable problems, but we require innovation in gene synthesis to accelerate progress,” said Dr. Tim Brears, Evonetix CEO, in the press release. “Our new office and lab space will enable integration of our teams of specialists to support the development and delivery of our highly parallel desktop platform, which will be available to every researcher to accelerate their ability to use biology on a scale not currently possible.”
Source:
Advertisement
Related to this article
Sanofi’s Jack Prior discusses how biopharmaceutical manufacturers can assess whether process data is ready for human and AI use, and the role of data quality, accessibility, governance, and AI in manufacturing.
Regulatory approvals, trial data, and major licensing deals in 2026 are accelerating subcutaneous biologics, cutting patient burden and reshaping biopharma strategy.
Today’s biopharma news highlights GSK’s myeloma strategy, Insilico’s AI longevity research, and innovations that may improve future treatment outcomes.
This episode of the BioPharm Brief highlights Roche’s Tam-Peli phase 3 survival data in relapsed small-cell lung cancer, Cellectis’ shift to in vivo gene editing for lipid disorders, and Phio Pharmaceuticals’ FDA briefing package for PH-762 in cutaneous squamous cell carcinoma.
Tambotatug pelitecan (Tam-Peli), a B7-H3-targeted antibody-drug conjugate, is the second of at least three B7-H3-targeted ADCs to post positive late-stage data in relapsed small-cell lung cancer this year.
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.
The BioPharm Brief covers Resolution Therapeutics’ completed enrollment of RTX001 in the EMERALD trial, Samsung Biologics’ $262 million manufacturing deal, and CordenPharma’s $80 million investment to expand sterile injectable capacity.
Advertisement
Advertisement